Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: SFW who wrote (22667)	1/15/1999 4:56:00 PM
From: Judy	Read Replies (2) \| Respond to of 50167

Abed, IMNX has excellent business potential but at this point no one is sure how to gauge the extent of the RA market, RA is far more debilitating than regular arithis. The problem could expand with the aging population, but beyond the baby-boomer generation, the US population is contracting. I liquidated my IMNX investment position before this last runup to have free capital when drug stocks such as PFE and WLA presented good buying opportunities. IMNX does not have the breadth of pipeline nor the consistency in performance that I look for in long-term investments. IMNX was a speculative investment for last year, and this year it is a trade stock. But that's just my view. IMNX may have far to go, but we won't know until the scripts data for Enbrel starts coming in. AMGN and BGEN 5-6 years ago are where IMNX is today ... I assumed you dumped AAPL before the fall.